Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High?

View original at finance.yahoo.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High? JPMorgan’s JPM shares reached a new all-time high of $327.78 yesterday, driven by optimism for the easing rate cycle and stronger U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JPMorgan is mulling entry into the crypto trading business

    80% confidence

  • NII (excluding Markets) expected to grow 5.5%

    80% confidence

  • NII (excluding Markets) expected to be nearly $92.2 billion in 2025 and $95 billion in 2026

    80% confidence

  • Zacks Consensus Estimate for earnings implies 2.9% and 3.5% year-over-year growth for 2025 and 2026, respectively

    80% confidence

  • Consensus mark for 2025 and 2026 revenues suggests a year-over-year rise of 2.8% and 3.9%, respectively

    80% confidence

  • NII expected to rise 6-7% in 2025

    80% confidence

  • JPMorgan remains well-placed for growth in 2026, backed by its robust capital markets business, dominant IB position, decent NII growth expectations and continued expansion through branch openings

    80% confidence

  • 2026 non-interest expenses expected to rise by more than $9 billion to $105 billion

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High? — Source | Via News | ViaNews EU